Drug Trial Radar · NCT06600841
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Mar 1, 2026
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- Fujian Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Fujian Provincial Hospital
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib in platinum-resistant relapsed/metastatic ovarian cancer.
Conditions
- Platinum-resistant Ovarian Cancer (PROC)
- Immunotherapy
Interventions
Immunotherapy(Adebrelimab)Drug
Adebrelimab plus non-platinum chemotherapy(Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel)and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
immunotherapy(Adebrelimab)Drug
anti-PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR)Time frame: From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.